AcelRx Pharmaceuticals Analyst Ratings
AcelRx Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/18/2023 | 852.49% | HC Wainwright & Co. | → $8 | Upgrades | Neutral → Buy |
| 03/14/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 08/17/2021 | 495.31% | HC Wainwright & Co. | $7 → $5 | Maintains | Buy |
| 08/13/2020 | 0.01% | Credit Suisse | $0.69 → $0.84 | Maintains | Underperform |
| 07/20/2020 | -17.85% | Credit Suisse | $1 → $0.69 | Downgrades | Neutral → Underperform |
| 03/17/2020 | 733.43% | HC Wainwright & Co. | $9 → $7 | Maintains | Buy |
| 11/11/2019 | 138.12% | Credit Suisse | $7 → $2 | Downgrades | Outperform → Neutral |
| 08/05/2019 | 733.43% | Credit Suisse | → $7 | Assumes | → Outperform |
| 07/10/2019 | — | Credit Suisse | Assumes | → Outperform | |
| 04/24/2019 | — | B. Riley Securities | Initiates Coverage On | → Buy | |
| 02/15/2019 | 733.43% | Credit Suisse | → $7 | Initiates Coverage On | → Outperform |
| 10/23/2018 | 971.56% | B. Riley Securities | → $9 | Initiates Coverage On | → Buy |
| 10/15/2018 | 852.49% | Jefferies | → $8 | Upgrades | Hold → Buy |
| 10/10/2018 | 1090.62% | Ladenburg Thalmann | $7 → $10 | Reiterates | Buy → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/18/2023 | 852.49% | HC Wainwright & Co. | → 8 美元 | 升级 | 中性 → 买入 |
| 03/14/2022 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
| 2021 年 8 月 17 日 | 495.31% | HC Wainwright & Co. | 7 美元 → 5 美元 | 维护 | 购买 |
| 08/13/2020 | 0.01% | 瑞士信贷 | 0.69 美元 → 0.84 美元 | 维护 | 表现不佳 |
| 2020 年 7 月 20 日 | -17.85% | 瑞士信贷 | $1 → 0.69 美元 | 降级 | 中性 → 跑赢大盘 |
| 03/17/2020 | 733.43% | HC Wainwright & Co. | 9 美元 → 7 美元 | 维护 | 购买 |
| 2019 年 11 月 11 日 | 138.12% | 瑞士信贷 | 7 美元 → 2 美元 | 降级 | 跑赢大盘 → 中性 |
| 2019 年 5 月 8 日 | 733.43% | 瑞士信贷 | → 7 美元 | 假设 | → 跑赢大盘 |
| 2019 年 10 月 7 日 | — | 瑞士信贷 | 假设 | → 跑赢大盘 | |
| 2019 年 4 月 24 日 | — | B. 莱利证券 | 启动覆盖开启 | → 购买 | |
| 02/15/2019 | 733.43% | 瑞士信贷 | → 7 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 10/23/2018 | 971.56% | B. 莱利证券 | → 9 美元 | 启动覆盖开启 | → 购买 |
| 10/15/2018 | 852.49% | 杰富瑞 | → 8 美元 | 升级 | 持有 → 买入 |
| 10/10/2018 | 1090.62% | 拉登堡塔尔曼 | 7 美元 → 10 美元 | 重申 | 购买 → 购买 |
What is the target price for AcelRx Pharmaceuticals (ACRX)?
AcelRx Pharmicals（ACRX）的目标价格是多少？
The latest price target for AcelRx Pharmaceuticals (NASDAQ: ACRX) was reported by HC Wainwright & Co. on August 18, 2023. The analyst firm set a price target for $8.00 expecting ACRX to rise to within 12 months (a possible 852.49% upside). 1 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月18日公布了AcelRX Pharmicals（纳斯达克股票代码：ACRX）的最新目标股价。该分析公司将目标股价定为8.00美元，预计ACRX将在12个月内上涨至852.49％（可能上涨852.49％）。去年有1家分析公司公布了评级。
What is the most recent analyst rating for AcelRx Pharmaceuticals (ACRX)?
AcelRx Pharmicals (ACRX) 的最新分析师评级是多少？
The latest analyst rating for AcelRx Pharmaceuticals (NASDAQ: ACRX) was provided by HC Wainwright & Co., and AcelRx Pharmaceuticals upgraded their buy rating.
AcelRx Pharmicals（纳斯达克股票代码：ACRX）的最新分析师评级由HC Wainwright & Co. 提供，AcelRX Pharmicals上调了买入评级。
When is the next analyst rating going to be posted or updated for AcelRx Pharmaceuticals (ACRX)?
AcelRx Pharmicals（ACRX）的下一份分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AcelRx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AcelRx Pharmaceuticals was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与AcelRx Pharmicals的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。AcelRx Pharmicals的最后一次评级是在2023年8月18日提交的，因此你应该预计下一个评级将在2024年8月18日左右公布。
Is the Analyst Rating AcelRx Pharmaceuticals (ACRX) correct?
分析师对AcelRx Pharmicals（ACRX）的评级是否正确？
While ratings are subjective and will change, the latest AcelRx Pharmaceuticals (ACRX) rating was a upgraded with a price target of $0.00 to $8.00. The current price AcelRx Pharmaceuticals (ACRX) is trading at is $0.84, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的AcelRx Pharmicals（ACRX）评级已上调，目标股价为0.00美元，至8.00美元。AcelRx Pharmicals（ACRX）的当前交易价格为0.84美元，在分析师的预测区间内。